WO2003028661A3 - Adjuvanted meningococcus compositions - Google Patents

Adjuvanted meningococcus compositions Download PDF

Info

Publication number
WO2003028661A3
WO2003028661A3 PCT/US2002/031726 US0231726W WO03028661A3 WO 2003028661 A3 WO2003028661 A3 WO 2003028661A3 US 0231726 W US0231726 W US 0231726W WO 03028661 A3 WO03028661 A3 WO 03028661A3
Authority
WO
WIPO (PCT)
Prior art keywords
meningococcus
adjuvanted
compositions
neisserial
cpg
Prior art date
Application number
PCT/US2002/031726
Other languages
French (fr)
Other versions
WO2003028661A2 (en
Inventor
Derek O'hagan
Nicholas Valiante
Original Assignee
Chiron Corp
Derek O'hagan
Nicholas Valiante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/010869 external-priority patent/WO2002080648A2/en
Application filed by Chiron Corp, Derek O'hagan, Nicholas Valiante filed Critical Chiron Corp
Priority to EP02800481A priority Critical patent/EP1438323A4/en
Priority to JP2003531997A priority patent/JP4522699B2/en
Priority to NZ532274A priority patent/NZ532274A/en
Priority to CA2462646A priority patent/CA2462646C/en
Priority to BR0213119-6A priority patent/BR0213119A/en
Priority to AU2002334844A priority patent/AU2002334844B2/en
Priority to MXPA04003186A priority patent/MXPA04003186A/en
Publication of WO2003028661A2 publication Critical patent/WO2003028661A2/en
Publication of WO2003028661A3 publication Critical patent/WO2003028661A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Abstract

A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a Neisserial antigen; (b) a CpG oligonucleotide; and (c) a biodegradable polymer microparticle.
PCT/US2002/031726 2001-10-03 2002-10-03 Adjuvanted meningococcus compositions WO2003028661A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP02800481A EP1438323A4 (en) 2001-10-03 2002-10-03 Adjuvanted meningococcus compositions
JP2003531997A JP4522699B2 (en) 2001-10-03 2002-10-03 Adjuvanted Meningococcus composition
NZ532274A NZ532274A (en) 2001-10-03 2002-10-03 Adjuvanted meningococcus compositions
CA2462646A CA2462646C (en) 2001-10-03 2002-10-03 Adjuvanted meningococcus compositions
BR0213119-6A BR0213119A (en) 2001-10-03 2002-10-03 Immunogenic composition and use thereof
AU2002334844A AU2002334844B2 (en) 2001-10-03 2002-10-03 Adjuvanted meningococcus compositions
MXPA04003186A MXPA04003186A (en) 2001-10-03 2002-10-03 Adjuvanted meningococcus compositions.

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US32692901P 2001-10-03 2001-10-03
US60/326,929 2001-10-03
PCT/US2002/010869 WO2002080648A2 (en) 2001-04-05 2002-04-05 Mucosal boosting following parenteral priming
USPCT/US02/10869 2002-04-05
US37354702P 2002-04-17 2002-04-17
US60/373,547 2002-04-17
US38067702P 2002-05-13 2002-05-13
US60/380,677 2002-05-13
US25443802A 2002-09-24 2002-09-24
USPCT/US02/30423 2002-09-24
US10/254,438 2002-09-24
US0230423 2002-09-24

Publications (2)

Publication Number Publication Date
WO2003028661A2 WO2003028661A2 (en) 2003-04-10
WO2003028661A3 true WO2003028661A3 (en) 2003-10-09

Family

ID=32601151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/031726 WO2003028661A2 (en) 2001-10-03 2002-10-03 Adjuvanted meningococcus compositions

Country Status (8)

Country Link
EP (1) EP1438323A4 (en)
JP (1) JP4522699B2 (en)
CN (1) CN100354297C (en)
AU (1) AU2002334844B2 (en)
BR (1) BR0213119A (en)
CA (1) CA2462646C (en)
NZ (1) NZ532274A (en)
WO (1) WO2003028661A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
DE60328481D1 (en) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic SLEEP-CAPACITIVE VACCINE CONTAINING THE ADJUVANZ CHITOSAN AND MENIGOKOKKENANTIGENE
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
ES2575014T3 (en) 2002-08-02 2016-06-23 Glaxosmithkline Biologicals S.A. Neisseria vaccine compositions comprising a combination of antigens
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
WO2004075829A2 (en) * 2003-01-30 2004-09-10 Chiron Corporation Adjuvanted influenza vaccine
EP2289546A3 (en) 2003-01-30 2011-03-30 Novartis Vaccines and Diagnostics S.r.l. Injectable vaccines against multiple meningococcal serogroups
US7731967B2 (en) * 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
EP1725266A4 (en) * 2004-02-20 2008-05-07 Hybridon Inc Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
WO2007013893A2 (en) * 2004-11-15 2007-02-01 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
KR101415864B1 (en) 2005-01-28 2014-07-09 갈렌바이오 인코포레이티드 Immunologically active compositions
US20080138431A1 (en) * 2005-03-02 2008-06-12 James Edward Eyles Pharmaceutical Composition
WO2009076158A1 (en) 2007-12-07 2009-06-18 Novartis Ag Compositions for inducing immune responses
CN101559225B (en) * 2008-04-18 2012-07-11 北京生物制品研究所 Meningococcus vaccine
CA3211102A1 (en) 2012-06-21 2013-12-27 Northwestern University Peptide conjugated particles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050075A2 (en) * 1999-02-26 2000-08-31 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
WO2000050006A2 (en) * 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278006A3 (en) * 1997-11-06 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
CA2317815A1 (en) * 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
EP1645631B1 (en) * 1998-05-01 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Neisseria antigens and compositions
PT1100468E (en) * 1998-07-29 2006-07-31 Chiron Corp MICROPARTICLES WITH ADSORVENT SURFACES, PROCESSES OF MANUFACTURE AND USE OF THE SAME
CA2346713A1 (en) * 1998-10-09 2000-04-20 Chiron Corporation Neisseria genomic sequences and methods of their use
ES2477194T3 (en) * 1999-04-30 2014-07-16 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens conserved
BR0108711A (en) * 2000-02-28 2004-06-22 Chiron Spa Heterologous expression of neisserial proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO2000050075A2 (en) * 1999-02-26 2000-08-31 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
WO2000050006A2 (en) * 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1438323A4 *

Also Published As

Publication number Publication date
CA2462646A1 (en) 2003-04-10
NZ532274A (en) 2006-02-24
CA2462646C (en) 2013-02-12
EP1438323A4 (en) 2007-08-01
AU2002334844B8 (en) 2003-04-14
CN100354297C (en) 2007-12-12
AU2002334844B2 (en) 2007-08-02
CN1599746A (en) 2005-03-23
JP2005526697A (en) 2005-09-08
WO2003028661A2 (en) 2003-04-10
JP4522699B2 (en) 2010-08-11
BR0213119A (en) 2004-12-28
EP1438323A2 (en) 2004-07-21

Similar Documents

Publication Publication Date Title
WO2003028661A3 (en) Adjuvanted meningococcus compositions
WO2004016805A3 (en) Immunostimulatory nucleic acids
AU2002332019A1 (en) Adjuvant compositions
AU2001255196A1 (en) Compositions and methods for enhancing immunogenicity of antigens
WO2002032450A3 (en) Vaccines
AU2002301801A1 (en) Cosmetic compositions containing an aminosilicone and a conditioner, and uses thereof
AU2002301803A1 (en) Cosmetic compositions containing an aminosilicone and a conditioner, and uses thereof
DE60210456D1 (en) SOLUBIZATION OF CAPSULES POLYSACCHARIDEN
WO2000050075A3 (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
WO2003080114A3 (en) Imidazoquinoline adjuvants for vaccines
MXPA03009234A (en) Cosmetic compositions containing dispersion polymers.
WO2003051392A3 (en) Streptococcus pneumoniae vaccine
HK1067891A1 (en) Influenza vaccine composition
GB9817052D0 (en) Vaccine
WO2004098491A3 (en) METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
WO2007013893A3 (en) Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
WO2004075829A3 (en) Adjuvanted influenza vaccine
AU2002353417A1 (en) Adjuvanted antigenic meningococcal compositions
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
WO2002018954A3 (en) Inhibition of cmv infection and dissemination
AU2001269269A1 (en) Silicone release coating compositions
WO2007034166A8 (en) Adjuvanted vaccine
AU2002307971A1 (en) Vaccine against the nile fever virus
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WPC Withdrawal of priority claims after completion of the technical preparations for international publication
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/003186

Country of ref document: MX

Ref document number: 2462646

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003531997

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 532274

Country of ref document: NZ

Ref document number: 2002334844

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002800481

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028241282

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002800481

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 532274

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002334844

Country of ref document: AU